本文選題：痰瘀伏邪 + 冠心病�。� 參考：《長春中醫(yī)藥大學(xué)》2016年碩士論文

【摘要】：目的:觀察中醫(yī)藥聯(lián)合西醫(yī)標(biāo)準(zhǔn)化治療不穩(wěn)定型心絞痛的臨床效果及對患者隨訪期間藥物的安全性的評價,同時與西醫(yī)標(biāo)準(zhǔn)化治療組比較在降低患者心肌梗死、猝死等心血管事件發(fā)生率等方面的優(yōu)勢。方法:采用隨機、多中心平行對照的試驗方法�？偣踩脒x患者160例,對照組80例和治療組80例,兩組患者均給予不穩(wěn)定型心絞痛的西醫(yī)標(biāo)準(zhǔn)化治療,治療組在西醫(yī)標(biāo)準(zhǔn)化治療上合用參紅通絡(luò)顆粒。療程為4周。以降低心肌梗死及猝死等心血管事件發(fā)生率為主要指標(biāo),血運重建的發(fā)生率、危險分層、生活質(zhì)量、心電圖療效等為次要指標(biāo),評價其臨床療效。結(jié)果:在降低心肌梗死及猝死率方面,中醫(yī)藥干預(yù)組明顯優(yōu)于對照組;改善心絞痛癥狀方面,中醫(yī)藥干預(yù)組明顯優(yōu)于對照組(P0.05);在降低血運重建的發(fā)生率方面,中醫(yī)藥干預(yù)可明顯降低血運重建率;在改善危險分層方面,中醫(yī)藥干預(yù)組明顯優(yōu)于對照組(P0.05);在改善生活質(zhì)量方面,與對照組比較,PL、AS、AF、TS、DP五大方面均有顯著性差異(P0.05);在改善心電圖療效方面,中醫(yī)藥干預(yù)組明顯優(yōu)于對照組(P0.05)。兩組患者試驗全過程各安全性指標(biāo)均未見明顯異常,且無嚴(yán)重不良反應(yīng)發(fā)生。結(jié)論:以伏邪為理論基礎(chǔ)的中醫(yī)藥,在不穩(wěn)定型心絞痛的治療方面療效明確,且臨床療效勝于西醫(yī)標(biāo)準(zhǔn)化治療組,安全性高,在降低心肌梗死及猝死率、血運重建發(fā)生率,改善心絞痛癥狀、危險分層及心電圖療效,提高患者生活質(zhì)量等各方面占有較大優(yōu)勢。
[Abstract]:Objective: to observe the clinical effect of traditional Chinese medicine combined with western medicine in the treatment of unstable angina pectoris and to evaluate the safety of drugs during follow-up. The advantages of cardiovascular events such as sudden death. Methods: a randomized, multicenter, parallel controlled trial was used. A total of 160 patients, 80 patients in the control group and 80 patients in the treatment group were given western standardized treatment of unstable angina pectoris. The course of treatment was 4 weeks. The clinical efficacy was evaluated by reducing the incidence of cardiovascular events such as myocardial infarction and sudden death, the incidence of revascularization, risk stratification, quality of life, and the efficacy of electrocardiogram. Results: in reducing myocardial infarction and sudden death rate, the TCM intervention group was obviously superior to the control group in improving the symptoms of angina pectoris, the TCM intervention group was obviously superior to the control group in reducing the incidence of revascularization. Chinese medicine intervention can significantly reduce the rate of revascularization; in improving the risk stratification, the Chinese medicine intervention group is significantly better than the control group (P 0.05); in improving the quality of life, Compared with the control group, there were significant differences in the five aspects of TSDP between the two groups, and the traditional Chinese medicine intervention group was better than the control group in improving the effect of electrocardiogram (ECG). There were no significant abnormalities and no serious adverse reactions in the whole process of the two groups. Conclusion: TCM based on Fuxie is more effective than Western medicine in the treatment of unstable angina pectoris. It is safe in reducing myocardial infarction and sudden death rate, and in the incidence of revascularization. Improving symptoms of angina pectoris, risk stratification and electrocardiogram effect, improving the quality of life of patients have a great advantage.
【學(xué)位授予單位】：長春中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2016
【分類號】：R259

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 何澤民;;中醫(yī)藥干預(yù)治療乙型肝炎病毒攜帶者的思路[J];新中醫(yī);2006年04期

2 張曼;張麗萍;劉海鵬;;應(yīng)激的神經(jīng)-內(nèi)分泌-免疫網(wǎng)絡(luò)機制及中醫(yī)藥干預(yù)研究進(jìn)展[J];神經(jīng)解剖學(xué)雜志;2008年02期

3 張文高;;中醫(yī)藥干預(yù)動脈粥樣硬化易損斑塊的實驗研究與思路[J];中國中西醫(yī)結(jié)合雜志;2008年05期

4 鄭景輝;李勇華;袁肇凱;;骨髓間充質(zhì)干細(xì)胞中醫(yī)藥干預(yù)研究的現(xiàn)狀及其前景和策略[J];遼寧中醫(yī)藥大學(xué)學(xué)報;2009年05期

5 ;我國深入研究中醫(yī)藥干預(yù)艾滋病[J];中醫(yī)藥導(dǎo)報;2009年07期

6 徐浩;;老年急性冠脈綜合征介入術(shù)后的中醫(yī)藥干預(yù)[J];中國中西醫(yī)結(jié)合雜志;2010年02期

7 沈安魯;彭代銀;方朝暉;;中醫(yī)藥干預(yù)糖尿病微血管并發(fā)癥的研究進(jìn)展[J];安徽醫(yī)藥;2012年04期

8 孫東建;蔣衛(wèi)民;;血壓變異的中醫(yī)藥干預(yù)研究進(jìn)展[J];新中醫(yī);2012年12期

9 訾勇;陳遠(yuǎn)平;何貴新;張清偉;;中醫(yī)藥干預(yù)血管內(nèi)皮生長因子的研究進(jìn)展[J];國醫(yī)論壇;2013年03期

10 謝仁廣;試論中醫(yī)藥干預(yù)過度現(xiàn)象[J];遼寧中醫(yī)雜志;1998年11期

相關(guān)會議論文 前10條

1 池曉玲;蔣俊民;田廣俊;蕭煥明;蔡高術(shù);謝玉寶;趙朋濤;;中醫(yī)藥干預(yù)對慢性乙型肝炎患者生存質(zhì)量的影響研究[A];第十八次全國中西醫(yī)結(jié)合肝病學(xué)術(shù)會議論文匯編[C];2009年

2 吳偉;;慢性完全閉塞病變介入與中醫(yī)藥干預(yù)[A];2011年中華中醫(yī)藥學(xué)會心病分會學(xué)術(shù)年會暨北京中醫(yī)藥學(xué)會心血管病專業(yè)委員會年會論文集[C];2011年

3 王秀英;;中醫(yī)藥干預(yù)重癥胰腺灸的護(hù)理[A];全國中醫(yī)、中西醫(yī)護(hù)理學(xué)術(shù)交流暨專題講座會議論文匯編[C];2008年

4 張莉;張文高;鄭廣娟;劉龍濤;朱慶均;張丹;張靜;徐敏;李寧;王顯剛;季選秀;吳敏;王姍姍;劉美霞;孟紅艷;于源滋;;動脈粥樣硬化易損斑塊及中醫(yī)藥干預(yù)研究[A];第五次全國中西醫(yī)結(jié)合養(yǎng)生學(xué)與康復(fù)醫(yī)學(xué)學(xué)術(shù)研討會論文集[C];2006年

5 于亮;劉郁;段紹斌;陳駿;吾買爾江·買買提;仝傳志;張增峰;董俞龍;董楊帆;耿加敏;丁志翔;;非手術(shù)治療慢性胰腺炎中醫(yī)藥干預(yù)療效的系統(tǒng)評價[A];第七屆中醫(yī)/中西醫(yī)結(jié)合循證醫(yī)學(xué)方法研討會會議材料[C];2013年

6 史文麗;劉燕玲;劉士敬;孫永強;宮Z，

本文編號：1815219